Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

151 articles from the last 30 days matching "Research"

ResearchBIORXIVToday

Preprint: Genotype-Based Severity Scoring System in Wolfram Syndrome

Wolfram syndrome is a rare genetic disorder that causes diabetes, vision loss, hearing loss, and brain problems. Researchers created a new scoring system that looks at the specific genetic mutations in the WFS1 gene to predict how severe a patient's symptoms will be and when they might appear. This system could help doctors understand what to expect for each patient based on their individual genetic makeup.

WHY IT MATTERSIf validated, this genotype-based scoring system could allow doctors to predict disease progression and symptom onset in individual Wolfram syndrome patients, enabling earlier intervention and personalized monitoring strategies.
Good to knowWolfram syndromeRead →
ResearchBIORXIVToday

Preprint: Fasting reverses PLN R14del-mediated cardiomyopathy through lysosomal reactivation

Scientists discovered that fasting may help reverse heart damage caused by a specific genetic mutation in the PLN gene called R14del. This mutation causes a common type of inherited heart disease where abnormal protein clumps build up in heart cells. The research shows that fasting activates the cell's cleanup system (lysosomes) to remove these harmful clumps and restore heart function.

WHY IT MATTERSIf confirmed in human studies, fasting could offer PLN R14del cardiomyopathy patients a non-drug intervention to potentially reverse heart damage, though this is currently only demonstrated in laboratory research and requires clinical validation.
👁 Watch this spacePLN R14del cardiomyopathydilated cardiomyopathyarrhythmogenic cardiomyopathyRead →
Clinical trialRSSToday

How 19 Points Changed My Grandson’s DMD Journey

A grandmother shares how a small change in how her grandson's condition was measured helped him qualify for a Duchenne muscular dystrophy (DMD) treatment trial. Researchers adjusted the scoring system by 19 points, which gave him a second chance to participate in the study. This story highlights how trial eligibility rules can sometimes be adjusted to help more patients access new treatments.

WHY IT MATTERSIf your child with DMD has been told they don't qualify for a trial, this story shows that eligibility criteria can sometimes be reconsidered or adjusted—it's worth asking your doctor whether similar flexibility might apply to your situation.
💬 Ask your doctorDuchenne muscular dystrophyRead →
ResearchPUBMEDToday

Aging and rare diseases: from epidemiology to a call to action.

Researchers in Italy studied how rare diseases affect older adults. They found that thousands of people are diagnosed with rare diseases after age 65, and thousands more who were diagnosed as children or young adults are now living into old age with these conditions. This study shows that rare diseases in elderly people are becoming more common and important to understand.

WHY IT MATTERSIf you or a family member has a rare disease and are aging, this research highlights that healthcare systems need better plans to care for older patients with rare conditions—which could lead to improved treatment strategies and support services tailored to your needs.
Good to knowRead →
Clinical trialCLINICALTRIALSToday

Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)

Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.

WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
You can act on thisnon-small cell lung cancerlocally advanced non-small cell lung cancermetastatic non-small cell lung cancerRead →
Clinical trialCLINICALTRIALSToday

New Clinical Trial: Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study (NCT01517945)

Researchers at Memorial Sloan Kettering Cancer Center are testing a smartphone app designed to help breast cancer and rare cancer survivors deal with the fear that their cancer might come back. The app uses a technique called Attention and Interpretation Modification (AIM) to help people change how they think about cancer recurrence. The study has enrolled 252 people and is no longer recruiting new participants, but the results could help many cancer survivors in the future.

WHY IT MATTERSThis trial addresses a common but often overlooked mental health challenge for cancer survivors—fear of recurrence—by testing a personalized, accessible mobile app intervention that could be widely available if proven effective.
👁 Watch this spaceBreast CancerRare CancersRead →
Clinical trialCLINICALTRIALSToday

Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)

Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.

WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.
You can act on thisnon-small cell lung cancer (NSCLC)locally advanced NSCLCmetastatic NSCLCRead →
GrantRSSToday

MDA Wings Over Wall Street gala returns to fund critical ALS research

The Muscular Dystrophy Association is holding its 26th annual fundraising gala in New York City on June 4 to raise money for ALS research. The event brings together financial leaders and medical researchers to support the search for treatments and cures for ALS, a disease that affects nerve cells controlling muscles.

WHY IT MATTERSFunding from this gala directly supports ALS research that could lead to new treatments, making it important for patients to know where research dollars are being invested and what progress is being made.
Good to knowamyotrophic lateral sclerosisRead →
PolicyRSSToday

Newborn SMA screening widely supported in U.K. survey

A large survey in the U.K. found that most people—including families of babies screened for SMA, people living with SMA, doctors, and the general public—strongly support newborn screening for spinal muscular atrophy. The main reason people liked the idea was that catching SMA early could help babies have better health outcomes. Researchers looked at what factors influenced people's opinions about this type of screening.

WHY IT MATTERSIf newborn SMA screening becomes standard in the U.K., babies diagnosed early could start treatment sooner, potentially preventing severe muscle weakness and improving their long-term quality of life.
Good to knowspinal muscular atrophyRead →
ResearchPUBMEDYesterday

Circular RNA therapeutics: a new class of long-acting RNA medicines for oncology, immunology, and rare diseases.

Scientists are studying a new type of medicine made from circular RNA, which is RNA shaped like a circle instead of a line. Because of their circular shape, these medicines may stay in the body longer and work better than current RNA medicines. Researchers are testing these circular RNA medicines to treat cancer, immune system diseases, and rare diseases.

WHY IT MATTERSCircular RNA therapeutics could eventually offer longer-lasting treatments for rare diseases with fewer doses needed, but patients should know that claims about safety and effectiveness vary depending on how the medicine is made—there's no one-size-fits-all answer yet.
Good to knowRead →
AdvocacyRSS2 days ago

PBC Summit Centers the Voices of People Living With the Disease

The PBC Foundation International Summit is a conference where people living with primary biliary cholangitis (PBC)—a rare liver disease—share their experiences and perspectives. Unlike typical medical conferences focused mainly on doctors and research, this summit puts patients' voices at the center of discussions. A woman with PBC explains what makes this event different and valuable for the community.

WHY IT MATTERSPatient-centered conferences like this one help people with PBC connect with others, learn directly from their peers' experiences, and ensure their needs shape future research and treatment discussions.
Good to knowprimary biliary cholangitisRead →
Clinical trialRSS2 days ago

How an EBV Vaccine Could Be a Major MS Disrupter

Scientists are testing a new vaccine against Epstein-Barr virus (EBV), a common virus that may trigger multiple sclerosis (MS). Early research suggests that preventing EBV infection could help prevent or reduce MS development. This vaccine could be a major breakthrough for people at risk of developing MS or those already living with the disease.

WHY IT MATTERSIf successful, an EBV vaccine could prevent MS from developing in the first place, offering a potential cure-like approach rather than just managing symptoms after diagnosis.
👁 Watch this spacemultiple sclerosisRead →
ResearchRSS2 days ago

Researchers ID compound that may slow Parkinson’s progression

Scientists at Florida International University found a compound called CTS2444-32 that may help slow Parkinson's disease by improving how mitochondria (the energy centers of cells) work. The compound works by reducing a protein called DRP1 that controls mitochondrial function, which helps prevent toxic proteins from building up in the brain—a key problem in Parkinson's.

WHY IT MATTERSIf CTS2444-32 proves effective in human trials, it could offer Parkinson's patients a new treatment option that targets the disease's underlying cause rather than just managing symptoms.
👁 Watch this spaceParkinson's diseaseRead →
ResearchRSS2 days ago

Regular exercise safely eases chronic pain in hemophilia: Study

A new study shows that regular exercise — including activities like walking, strength training, and balance work — is safe and helpful for people with hemophilia of all ages. The research found that exercise can reduce chronic pain, improve how well people can move and function, and make life better overall. The key is that exercise programs need to be carefully designed for each person's needs.

WHY IT MATTERSPeople with hemophilia often avoid exercise due to bleeding concerns, but this study provides evidence that structured exercise can safely reduce pain and improve daily functioning without increasing bleeding risk.
💬 Ask your doctorhemophilia Ahemophilia BRead →
ResearchRSS2 days ago

Wrist sensors reveal physical activity gaps for children with PH in study

A new study used wrist sensors to track physical activity in children with pulmonary hypertension (a condition where blood pressure in the lungs is too high). Researchers found that kids with this condition exercise less intensely and for shorter periods than healthy children. Children with more severe cases had even bigger drops in exercise intensity.

WHY IT MATTERSUnderstanding how pulmonary hypertension limits children's physical activity can help doctors and families set realistic exercise goals and monitor whether treatments are helping kids stay more active.
💬 Ask your doctorpulmonary hypertensionRead →
AdvocacyRSS2 days ago

Artemis II reminds me to dream big for a pulmonary hypertension cure

This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.

WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
Good to knowpulmonary hypertensionRead →
ResearchRSS2 days ago

AAN 2026: Crexont linked to more on time in new Parkinson’s study

Researchers found that a Parkinson's disease medication called Crexont helped patients spend more time feeling better and less time experiencing symptoms when they switched from other levodopa treatments. The study showed improvements in movement control and daily functioning across different patient groups. This is early-stage research being presented at a medical conference.

WHY IT MATTERSIf you take levodopa for Parkinson's and struggle with 'off' periods when symptoms return between doses, Crexont may offer a way to extend your good symptom control time throughout the day.
💬 Ask your doctorParkinson's diseaseRead →
ResearchRSS2 days ago

Smartphone data may help detect rare lung disease earlier, study suggests

Researchers found that data from smartphones and wearable devices, collected over several years through a health app, can help doctors identify people with a rare lung disease called idiopathic pulmonary arterial hypertension (IPAH) earlier than before. The study used information like heart rate and activity levels from the My Heart Counts app to spot differences between people with IPAH and healthy people. This discovery could lead to faster diagnosis of this serious condition.

WHY IT MATTERSEarlier detection of IPAH could allow patients to start treatment sooner, potentially slowing disease progression and improving outcomes for this condition that currently has no cure.
Good to knowidiopathic pulmonary arterial hypertensionRead →
ResearchRSS2 days ago

Exposure to pesticide HCB may raise risk of ALS, new study finds

A new study from Denmark found that people with higher levels of HCB (a pesticide that was banned in many countries) in their blood may have a higher risk of developing ALS, a disease that affects nerve cells and causes muscle weakness. HCB was used as a pesticide in the past but is no longer allowed in many places because it can be harmful to health. This research suggests that exposure to this old pollutant might be connected to ALS risk.

WHY IT MATTERSIf you have ALS or a family history of it, understanding environmental risk factors like HCB exposure could help you and your doctor identify potential causes and discuss ways to reduce exposure to similar pollutants.
💬 Ask your doctoramyotrophic lateral sclerosisRead →
ResearchRSS2 days ago

AI may help hemophilia patients detect joint bleeding at home

Researchers developed an artificial intelligence tool that can accurately detect bleeding inside joints in adults with hemophilia by analyzing ultrasound images. This technology could eventually allow patients to get ultrasound scans at home instead of traveling to a hospital or clinic. Early detection of joint bleeding is important because it helps prevent long-term damage to the joints.

WHY IT MATTERSHemophilia patients currently must travel to medical facilities for ultrasound imaging to detect joint bleeds; this AI tool could enable home-based monitoring, reducing travel burden and potentially catching bleeding episodes earlier.
👁 Watch this spaceHemophilia AHemophilia BRead →
Page 1 of 8Next →

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases